These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 25963001)
1. Inappropriate Use of Radioactive Iodine for Low-Risk Papillary Thyroid Cancer Is Most Common in Regions with Poor Access to Healthcare. Marti JL; Davies L; Haymart MR; Roman BR; Tuttle RM; Morris LG Thyroid; 2015 Jul; 25(7):865-6. PubMed ID: 25963001 [No Abstract] [Full Text] [Related]
2. The rationale of patients with early-stage papillary thyroid cancer for accepting or rejecting radioactive iodine remnant ablation. Sawka AM; Rilkoff H; Tsang RW; Brierley JD; Rotstein L; Ezzat S; Asa SL; Segal P; Kelly C; Zahedi A; Gafni A; Goldstein DP Thyroid; 2013 Feb; 23(2):246-7. PubMed ID: 23009127 [No Abstract] [Full Text] [Related]
3. The 2009 American Thyroid Association guidelines modestly reduced radioactive iodine use for thyroid cancers less than 1 cm. Roman BR; Feingold JH; Patel SG; Shaha AR; Shah JP; Tuttle RM; Epstein AJ Thyroid; 2014 Oct; 24(10):1549-50. PubMed ID: 25065817 [No Abstract] [Full Text] [Related]
4. Application of the new American Thyroid Association guidelines leads to a substantial rate of completion total thyroidectomy to enable adjuvant radioactive iodine. Kluijfhout WP; Pasternak JD; Drake FT; Beninato T; Shen WT; Gosnell JE; Suh I; C L; Duh QY Surgery; 2017 Jan; 161(1):127-133. PubMed ID: 27855968 [TBL] [Abstract][Full Text] [Related]
5. Association between excessive urinary iodine excretion and failure of radioactive iodine thyroid ablation in patients with papillary thyroid cancer. Sohn SY; Choi JY; Jang HW; Kim HJ; Jin SM; Kim SW; Suh S; Hur KY; Kim JH; Chung JH; Kim SW Thyroid; 2013 Jun; 23(6):741-7. PubMed ID: 23205883 [TBL] [Abstract][Full Text] [Related]
6. Too Much of a Good Thing: Radioactive Iodine Ablation Use for Micropapillary Thyroid Carcinoma. Chae AW; Martinez SR Am Surg; 2018 May; 84(5):637-643. PubMed ID: 29966562 [TBL] [Abstract][Full Text] [Related]
7. Timing of Adjuvant Radioactive Iodine Therapy Does Not Affect Overall Survival in Low- and Intermediate-Risk Papillary Thyroid Carcinoma. Suman P; Wang CH; Moo-Young TA; Prinz RA; Winchester DJ Am Surg; 2016 Sep; 82(9):807-14. PubMed ID: 27670568 [TBL] [Abstract][Full Text] [Related]
8. Thyroid ablation with 1.1 GBq (30 mCi) iodine-131 in patients with papillary thyroid carcinoma at intermediate risk for recurrence. Rosário PW; Calsolari MR Thyroid; 2014 May; 24(5):826-31. PubMed ID: 24283207 [TBL] [Abstract][Full Text] [Related]
9. The results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer, based on Memorial Sloan-Kettering Cancer Center risk group stratification. Nixon IJ; Ganly I; Patel SG; Palmer FL; Di Lorenzo MM; Grewal RK; Larson SM; Tuttle RM; Shaha A; Shah JP Thyroid; 2013 Jun; 23(6):683-94. PubMed ID: 23742290 [TBL] [Abstract][Full Text] [Related]
10. Use of evidence-based guidelines reduces radioactive iodine treatment in patients with low-risk differentiated thyroid cancer. Sacks W; Wong RM; Bresee C; Braunstein GD Thyroid; 2015 Apr; 25(4):377-85. PubMed ID: 25578116 [TBL] [Abstract][Full Text] [Related]
11. Well-differentiated thyroid carcinoma: the role of post-operative radioactive iodine administration. Patel SS; Goldfarb M J Surg Oncol; 2013 May; 107(6):665-72. PubMed ID: 23192391 [TBL] [Abstract][Full Text] [Related]
12. The impact of iodinated contrast agent administered during preoperative computed tomography scan on body iodine pool in patients with differentiated thyroid cancer preparing for radioactive iodine treatment. Sohn SY; Choi JH; Kim NK; Joung JY; Cho YY; Park SM; Kim TH; Jin SM; Bae JC; Lee SY; Chung JH; Kim SW Thyroid; 2014 May; 24(5):872-7. PubMed ID: 24295076 [TBL] [Abstract][Full Text] [Related]
13. The impact of socioeconomic status on the use of adjuvant radioactive iodine for papillary thyroid cancer. Zevallos JP; Xu L; Yiu Y Thyroid; 2014 Apr; 24(4):758-63. PubMed ID: 24378070 [TBL] [Abstract][Full Text] [Related]
14. Radioactive iodine use in patients with low- and intermediate-risk papillary thyroid cancer. Nixon IJ; Ganly I Future Oncol; 2013 Jul; 9(7):921-3. PubMed ID: 23837752 [No Abstract] [Full Text] [Related]
15. Is radioiodine ablation necessary for patients with low-risk papillary thyroid carcinoma and tumor >4 cm? Rosario PW Eur J Surg Oncol; 2017 Sep; 43(9):1802-1803. PubMed ID: 28743373 [No Abstract] [Full Text] [Related]
16. Decision aid on radioactive iodine treatment for early stage papillary thyroid cancer: update to study protocol with follow-up extension. Sawka AM; Straus S; Rodin G; Thorpe KE; Ezzat S; Gafni A; Goldstein DP Trials; 2015 Jul; 16():302. PubMed ID: 26169592 [TBL] [Abstract][Full Text] [Related]
17. Adjuvant therapy with 131-iodine in patients with elevated serum thyroglobulin after reoperation due to papillary thyroid carcinoma lymph node metastases. Rosario PW; Mourão GF; Siman TL; Calsolari MR Endocrine; 2015 May; 49(1):279-82. PubMed ID: 25205448 [No Abstract] [Full Text] [Related]
18. Patterns of use and cost for inappropriate radioactive iodine treatment for thyroid cancer in the United States: use and misuse. Goffredo P; Thomas SM; Dinan MA; Perkins JM; Roman SA; Sosa JA JAMA Intern Med; 2015 Apr; 175(4):638-40. PubMed ID: 25686394 [No Abstract] [Full Text] [Related]
19. Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer. Ruel E; Thomas S; Dinan M; Perkins JM; Roman SA; Sosa JA J Clin Endocrinol Metab; 2015 Apr; 100(4):1529-36. PubMed ID: 25642591 [TBL] [Abstract][Full Text] [Related]
20. Association of tumor size and focality with recurrence/persistence in papillary thyroid cancer patients treated with total thyroidectomy along with radioactive-iodine ablation and TSH suppression. Khan M; Syed AA; Khan AI; Hussain SR; Urooj N Updates Surg; 2018 Mar; 70(1):121-127. PubMed ID: 28550398 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]